US subsidiary of Lundbeck launches Northera (droxidopa) capsules in US.
M2 PHARMA-September 4, 2014-US subsidiary of Lundbeck launches Northera (droxidopa) capsules in US
(C)2014 M2 COMMUNICATIONS
The United States subsidiary of Lundbeck, a Danish global pharmaceutical company, has introduced Northera (droxidopa) capsules in the USA, it was reported yesterday.
The product is to be used for the treatment of neurogenic orthostatic hypotension, for which it has received approval from the US Food and Drug Administration. It is indicated to treat orthostatic dizziness, lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Lundbeck US president, Staffan Schuberg, stated that for people living with symptomatic neurogenic orthostatic hypotension, the availability of Northera is likely to offer a new treatment option to discuss with their healthcare provider.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 4, 2014|
|Previous Article:||EMD Serono Research and Development Institute signs collaborative research agreement with Massachusetts General Hospital.|
|Next Article:||Macrocure completes patient enrolment in double-blind, Phase III clinical trial of CureXcell.|